<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Engene Holdings Inc. Common Stock — News on 6ix</title>
<link>https://6ix.com/company/engene-holdings-inc-common-stock</link>
<description>Latest news and press releases for Engene Holdings Inc. Common Stock on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 07 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/engene-holdings-inc-common-stock" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835636b78dffbe2df0ef3df.webp</url>
<title>Engene Holdings Inc. Common Stock</title>
<link>https://6ix.com/company/engene-holdings-inc-common-stock</link>
</image>
<item>
<title>enGene Announces Name Change to enGene Therapeutics Inc.</title>
<link>https://6ix.com/company/engene-holdings-inc-common-stock/news/engene-announces-name-change-to-engene-therapeutics-inc</link>
<guid isPermaLink="true">https://6ix.com/company/engene-holdings-inc-common-stock/news/engene-announces-name-change-to-engene-therapeutics-inc</guid>
<pubDate>Tue, 07 Apr 2026 04:00:00 GMT</pubDate>
<description>Name change reflects transition towards potential commercial organization in 2027 Planned Biologics License Application (BLA) submission for detalimogene in</description>
</item>
<item>
<title>enGene Reports First Quarter 2026 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/engene-holdings-inc-common-stock/news/engene-reports-first-quarter-2026-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/engene-holdings-inc-common-stock/news/engene-reports-first-quarter-2026-financial-results-and-provides-business-update</guid>
<pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
<description>LEGEND pivotal cohort update planned for a spring 2026 medical conference 12-month complete response data from LEGEND pivotal cohort expected in 2H 2026</description>
</item>
<item>
<title>enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026</title>
<link>https://6ix.com/company/engene-holdings-inc-common-stock/news/engene-participate-guggenheim-emerging-outlook-130000697</link>
<guid isPermaLink="true">https://6ix.com/company/engene-holdings-inc-common-stock/news/engene-participate-guggenheim-emerging-outlook-130000697</guid>
<pubDate>Wed, 04 Feb 2026 13:00:00 GMT</pubDate>
<description>BOSTON & MONTREAL, February 04, 2026--enGene Holdings Inc. (Nasdaq: ENGN or "enGene"), a clinical-stage, non-viral genetic medicines company, today announced that Ron Cooper, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026, at 2:30 p.m. ET.</description>
</item>
<item>
<title>enGene Announces Expanded $125 Million Debt Facility with Hercules Capital, Inc.</title>
<link>https://6ix.com/company/engene-holdings-inc-common-stock/news/engene-announces-expanded-125-million-223500724</link>
<guid isPermaLink="true">https://6ix.com/company/engene-holdings-inc-common-stock/news/engene-announces-expanded-125-million-223500724</guid>
<pubDate>Tue, 20 Jan 2026 22:35:00 GMT</pubDate>
<description>BOSTON & MONTREAL, January 20, 2026--enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced that it has entered into an amendment to an amended and restated loan and security agreement (as amended, the "Loan Agreement") with two of its subsidiaries and Hercules Capital, Inc. (NYSE: HTGC) ("Hercules"), as agent, for up to US$125 million. Access to the additional non-dilutive capital strengthens enGene’s balance sheet</description>
</item>
<item>
<title>enGene Reports Full Year 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/engene-holdings-inc-common-stock/news/engene-reports-full-2025-financial-210300127</link>
<guid isPermaLink="true">https://6ix.com/company/engene-holdings-inc-common-stock/news/engene-reports-full-2025-financial-210300127</guid>
<pubDate>Mon, 22 Dec 2025 21:03:00 GMT</pubDate>
<description>BOSTON & MONTREAL, December 22, 2025--enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the full year ended October 31, 2025, and provided a business update.</description>
</item>
<item>
<title>Specific Biologics Welcomes Accomplished Biotechnology Leader Dr. Richard Glickman to its Board of Directors</title>
<link>https://6ix.com/company/engene-holdings-inc-common-stock/news/specific-biologics-welcomes-accomplished-biotechnology-leader-dr-richard-glickman-to-its-board-of-directors-1</link>
<guid isPermaLink="true">https://6ix.com/company/engene-holdings-inc-common-stock/news/specific-biologics-welcomes-accomplished-biotechnology-leader-dr-richard-glickman-to-its-board-of-directors-1</guid>
<pubDate>Tue, 16 Dec 2025 15:00:00 GMT</pubDate>
<description>Specific Biologics Inc. ("Specific Biologics"), a precision in vivo genome editing company developing highly predictable, efficient and specific Dualase® genome editors to treat the untreatable, today announced the appointment of Dr. Richard Glickman to its Board of Directors.</description>
</item>
<item>
<title>enGene’s Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness</title>
<link>https://6ix.com/company/engene-holdings-inc-common-stock/news/engene-detalimogene-selected-fda-manufacturing-123000272</link>
<guid isPermaLink="true">https://6ix.com/company/engene-holdings-inc-common-stock/news/engene-detalimogene-selected-fda-manufacturing-123000272</guid>
<pubDate>Tue, 02 Dec 2025 12:30:00 GMT</pubDate>
<description>BOSTON & MONTREAL, December 02, 2025--enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced that the U.S. Food and Drug Administration (FDA) has selected detalimogene voraplasmid (also known as detalimogene and previously EG-70) to participate in the Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) Program. Detalimogene is a novel, investigational, non-viral gene therapy for pati</description>
</item>
<item>
<title>enGene to Present at the Piper Sandler 37th Annual Healthcare Conference</title>
<link>https://6ix.com/company/engene-holdings-inc-common-stock/news/engene-present-piper-sandler-37th-123000096</link>
<guid isPermaLink="true">https://6ix.com/company/engene-holdings-inc-common-stock/news/engene-present-piper-sandler-37th-123000096</guid>
<pubDate>Tue, 25 Nov 2025 12:30:00 GMT</pubDate>
<description>BOSTON & MONTREAL, November 25, 2025--enGene Holdings Inc. (Nasdaq: ENGN or "enGene"), a clinical-stage, non-viral genetic medicines company, today announced that Alex Nichols, Ph.D., Chief Strategy and Operations Officer, will present at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025, at 12:10 p.m. ET.</description>
</item>
<item>
<title>enGene Announces Pricing of $130 Million Public Offering of Common Shares and Pre-Funded Warrants</title>
<link>https://6ix.com/company/engene-holdings-inc-common-stock/news/engene-announces-pricing-130-million-052700182</link>
<guid isPermaLink="true">https://6ix.com/company/engene-holdings-inc-common-stock/news/engene-announces-pricing-130-million-052700182</guid>
<pubDate>Thu, 13 Nov 2025 05:27:00 GMT</pubDate>
<description>BOSTON & MONTREAL, November 13, 2025--enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced the pricing of its previously announced underwritten public offering of 12,558,823 common shares at a public offering price of $8.50 per share and pre-funded warrants to purchase 2,735,295 shares of its common shares at an offering price of $8.4999 per pre-funded warrant, in each case, before underwriting discounts and commis</description>
</item>
<item>
<title>enGene Announces Proposed Public Offering of Common Shares</title>
<link>https://6ix.com/company/engene-holdings-inc-common-stock/news/engene-announces-proposed-public-offering-210100538</link>
<guid isPermaLink="true">https://6ix.com/company/engene-holdings-inc-common-stock/news/engene-announces-proposed-public-offering-210100538</guid>
<pubDate>Wed, 12 Nov 2025 21:01:00 GMT</pubDate>
<description>BOSTON & MONTREAL, November 12, 2025--enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced that it has commenced an underwritten public offering of its common shares. All common shares to be sold in the offering will be offered by enGene. In addition, enGene intends to grant the underwriters a 30-day option to purchase up to a number of additional common shares equal to 15% of the total number of common shares sold</description>
</item>
<item>
<title>Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 Months</title>
<link>https://6ix.com/company/engene-holdings-inc-common-stock/news/detalimogene-demonstrates-improved-complete-response-123000606</link>
<guid isPermaLink="true">https://6ix.com/company/engene-holdings-inc-common-stock/news/detalimogene-demonstrates-improved-complete-response-123000606</guid>
<pubDate>Tue, 11 Nov 2025 12:30:00 GMT</pubDate>
<description>BOSTON & MONTREAL, November 11, 2025--enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today reported additional preliminary data from the pivotal cohort of its ongoing, Phase 2 LEGEND trial of detalimogene voraplasmid (also known as detalimogene and previously EG-70) in high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients with carcinoma in situ (CIS) with or without conc</description>
</item>
<item>
<title>enGene to Host Conference Call to Provide Update on Pivotal Cohort of LEGEND Trial</title>
<link>https://6ix.com/company/engene-holdings-inc-common-stock/news/engene-host-conference-call-pivotal-210500320</link>
<guid isPermaLink="true">https://6ix.com/company/engene-holdings-inc-common-stock/news/engene-host-conference-call-pivotal-210500320</guid>
<pubDate>Mon, 10 Nov 2025 21:05:00 GMT</pubDate>
<description>BOSTON & MONTREAL, November 10, 2025--enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced that it will host a conference call and webcast tomorrow, November 11, 2025, at 8:00 a.m. ET to discuss new preliminary data from its pivotal cohort in the ongoing LEGEND trial of its novel, non-viral gene therapy candidate, detalimogene voraplasmid (also known as detalimogene, and previously EG-70) for patients with high-r</description>
</item>
<item>
<title>enGene to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/engene-holdings-inc-common-stock/news/engene-participate-upcoming-investor-conferences-220000404</link>
<guid isPermaLink="true">https://6ix.com/company/engene-holdings-inc-common-stock/news/engene-participate-upcoming-investor-conferences-220000404</guid>
<pubDate>Thu, 06 Nov 2025 22:00:00 GMT</pubDate>
<description>BOSTON & MONTREAL, November 06, 2025--enGene Holdings Inc. (Nasdaq: ENGN or "enGene"), a clinical-stage, non-viral genetic medicines company, today announced that management will participate in the following investor conferences in November:</description>
</item>
<item>
<title>enGene Named a BioSpace 2026 Best Places to Work Winner</title>
<link>https://6ix.com/company/engene-holdings-inc-common-stock/news/engene-named-biospace-2026-best-183500913</link>
<guid isPermaLink="true">https://6ix.com/company/engene-holdings-inc-common-stock/news/engene-named-biospace-2026-best-183500913</guid>
<pubDate>Tue, 04 Nov 2025 18:35:00 GMT</pubDate>
<description>BOSTON & MONTREAL, November 04, 2025--enGene Holdings Inc. ("enGene" or the "Company") (Nasdaq: ENGN), a clinical-stage, non-viral genetic medicines company, today announced that BioSpace has named the company to its 2026 Best Places to Work. enGene is among 50 U.S. operating employers recognized as one of the most desirable workplaces in the life sciences industry.</description>
</item>
<item>
<title>enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/engene-holdings-inc-common-stock/news/engene-reports-inducement-grants-under-200300560</link>
<guid isPermaLink="true">https://6ix.com/company/engene-holdings-inc-common-stock/news/engene-reports-inducement-grants-under-200300560</guid>
<pubDate>Wed, 01 Oct 2025 20:03:00 GMT</pubDate>
<description>BOSTON & MONTREAL, October 01, 2025--enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today reported the grant of inducement equity awards to four newly-hired employees, including Hussein Sweiti, M.D., MSc, Chief Medical Officer, with a grant date of September 30, 2025. The inducement award for Dr. Sweiti consists of a non-qualified stock option to purchase an aggregate 600,000 of the Company's common shares. The inducement aw</description>
</item>
<item>
<title>enGene Appoints Hussein Sweiti, M.D., MSc, as Chief Medical Officer</title>
<link>https://6ix.com/company/engene-holdings-inc-common-stock/news/engene-appoints-hussein-sweiti-m-113000740</link>
<guid isPermaLink="true">https://6ix.com/company/engene-holdings-inc-common-stock/news/engene-appoints-hussein-sweiti-m-113000740</guid>
<pubDate>Tue, 30 Sep 2025 11:30:00 GMT</pubDate>
<description>BOSTON & MONTREAL, September 30, 2025--enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicine company, today announced that Hussein Sweiti, M.D., MSc, was appointed Chief Medical Officer, effective September 29, 2025.</description>
</item>
<item>
<title>enGene Reports Third Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/engene-holdings-inc-common-stock/news/engene-reports-third-quarter-2025-200300421</link>
<guid isPermaLink="true">https://6ix.com/company/engene-holdings-inc-common-stock/news/engene-reports-third-quarter-2025-200300421</guid>
<pubDate>Thu, 11 Sep 2025 20:03:00 GMT</pubDate>
<description>BOSTON & MONTREAL, September 11, 2025--enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral gene therapy company, today announced its financial results for the third quarter ended July 31, 2025, and provided a business update.</description>
</item>
<item>
<title>enGene Achieves Target Enrollment Milestone for LEGEND Trial Pivotal Cohort</title>
<link>https://6ix.com/company/engene-holdings-inc-common-stock/news/engene-achieves-target-enrollment-milestone-113000612</link>
<guid isPermaLink="true">https://6ix.com/company/engene-holdings-inc-common-stock/news/engene-achieves-target-enrollment-milestone-113000612</guid>
<pubDate>Wed, 03 Sep 2025 11:30:00 GMT</pubDate>
<description>BOSTON & MONTREAL, September 03, 2025--enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral gene therapy company, today announced it has achieved its target enrollment milestone of 100 patients for the pivotal cohort of its ongoing, open-label, multi-cohort Phase 2 LEGEND trial of detalimogene voraplasmid ("detalimogene" and previously EG-70) in patients with high-risk, non-muscle invasive bladder cancer (NMIBC). LEGEND’s pivotal Cohort 1 is studying detali</description>
</item>
<item>
<title>enGene Announces Board and Leadership Appointments to Support Commercial Readiness</title>
<link>https://6ix.com/company/engene-holdings-inc-common-stock/news/engene-announces-board-leadership-appointments-120000365</link>
<guid isPermaLink="true">https://6ix.com/company/engene-holdings-inc-common-stock/news/engene-announces-board-leadership-appointments-120000365</guid>
<pubDate>Tue, 08 Jul 2025 12:00:00 GMT</pubDate>
<description>BOSTON & MONTREAL, July 08, 2025--enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage, non-viral gene-based immunotherapy company, today announced the appointment of three new members to its Board of Directors: Philip Astley-Sparke, William Grossman, M.D., Ph.D., and Michael Heffernan, R.Ph. Their combined experience across gene therapy, oncology, clinical development, and global product launches will support enGene’s strategic transition toward planned commerciali</description>
</item>
<item>
<title>FDA Grants RMAT Designation for enGene’s Detalimogene, Enabling Potential for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer</title>
<link>https://6ix.com/company/engene-holdings-inc-common-stock/news/fda-grants-rmat-designation-engene-120000713</link>
<guid isPermaLink="true">https://6ix.com/company/engene-holdings-inc-common-stock/news/fda-grants-rmat-designation-engene-120000713</guid>
<pubDate>Wed, 25 Jun 2025 12:00:00 GMT</pubDate>
<description>BOSTON & MONTREAL, June 25, 2025--enGene Holdings Inc. (Nasdaq: ENGN, or "enGene" or the "Company"), a clinical-stage, non-viral gene-based immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to detalimogene voraplasmid (also known as detalimogene, and previously EG-70), the Company’s lead investigational therapy for the treatment of high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, no</description>
</item>
</channel>
</rss>